Delcath Systems Inc.

Delcath Announces Further Results From Neuroendocrine Tumor Cohort Presented at European Multidisciplinary Cancer Congress

Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress

Positive Phase 2 Trial Results From Neuroendocrine Tumor Cohort Presented at CIRSE

Delcath to Base European Operations in Galway, Ireland

NEW YORK and STOCKHOLM, September 25, 2011 - Delcath Systems (NASDAQ: DCTH) announced that James F.

NEW YORK and STOCKHOLM, September 23, 2011 - March 2011 Data Confirm Strong Treatment Effect of Chemosaturation Delcath Systems (NASDAQ: DCTH) announced today that James F.

MORE..

NEW YORK and MUNICH, September 13, 2011 - Chemosaturation Demonstrates Clinically Meaningful Tumor Response with Unresectable Neuroendocrine Tumors in the Liver Delcath Systems, Inc.

MORE..

Older News

NEW YORK, August 2, 2011 - - Company Receives Grant from IDA Ireland to Support Initial Staffing Delcath Systems, Inc.

MORE..